eliminate Fcγ receptor
binding and minimize
associated toxicity

Inactive
Fc Domain-20% Change fr
Baseli% ChangeBasebinding and minimize
associated toxicity

Fc Domain

Evorpacept-20

Evorpacept plus Enfortumab Vedotin in Patients with Locally Advanced or Metastatic
Urothelial Carcinoma (la/mUC): Phase 1a Dose Escalation Results
-60

SIRPα

-80

Complete Response

Evorpacept

Partial Response

Progressive Disease

Cancer Cell

CD47

Fc Receptor

-100

-40
100
-60
80
-80
60
-100
40

Nectin-4Stable Disease

Enfortumab Vedotin
Evorpacept

Not Evaluable

Macrophage% Change from Measurable% Change from Measurable
Baseline Lesion
Baseline Lesion-40

Progressive Disease

Abstract# 4575

Complete Response20

Not Evaluable

Partial Response

Progressive Disease

Stable Disease

Not Evaluable

0

Samuel A Funt , Petros Grivas², Xin Gao³, Daniel Vaena⁴, Tian Zhang⁵, Matthew Milowsky⁶, Mayank Rao⁷, Haiying Liu⁷, Kimberly Tipton⁷, Xuebei An⁷, Christine Ju⁷, Feng Jin⁷, Alison Forgie⁷, Sophia Randolph⁷, Athanasios C Tsiatis⁷, and Rohit K Jain⁸
100

1

SIRPα

Cancer Cell

CD47

80

SIRPα

100
-20

Cancer Cell

CD47

80
-40

6
60
Fc Receptor
Memorial Sloan Kettering Cancer Center, NY, USA; 2Fred Hutchinson Cancer Research Center, University ofWashington, Seattle, WA, USA; 3Massachusetts General
Hospital, Boston, MA, USA; 4West Cancer Center, Germantown, TN, USA; 5UniversityofTexas
Southwestern,
Dallas,TX,
USA;
UniversityofNorth
Carolina,
Chapel
Hill,
NC,
USA;
60
Fc Receptor
Nectin-4
7
8-60
ALX Oncology Inc., South San Francisco, CA, USA; Moffitt Cancer Center, Tampa, FL, USA
Nectin-4
40
Enfortumab Vedotin
Macrophageassociated toxicity (Figure 1).

Partial Response

Enfortumab Vedotin 1.25 mg/kg IV
on Days 1, 8, and 15 of a 28-Day Cycle

antibody-like PK.
• Molecular weight ishalf the size of typicalantibody.

CD47
Nectin-4

Backfill Cohort

Macrophage-60-80Results-100-80

Complete Response

Partial Response

Stable Disease
Stable Disease

20 mg/kg
IV Q2W that can activate the adaptive• The ADC payload may resultEvorpacept
in the generationof neoantigens
Dose Level1
immuneresponse.
Evorpacept 20 mg/kg IV Q2W
Enfortumab Vedotin 1.25 mg/kg IV
on Days 1, 8, and 15 of a 28-Day Cycle
Enfortumab Vedotin 1.25 mg/kg IV
on Days 1, 8, and 15 of a 28-Day Cycle

80

20
followed by lung(38.5%) and liver (30.8%).
0-20• Most patients (89.3%)
had received ≥2 prior lines of therapy.

Methods

Backfill Cohort

Evorpacept 20 mg/kg IV Q2W + Enfortumab Vedotin

ASPEN-07 Phase 1a Design Backfill Cohort

Evorpacept 20 mg/kg IV Q2W + Enfortumab Vedotin• The primary Phase 1a objective is to characterize the safety and tolerability of evorpacept
Dose Level
2
administeredin combination
with enfortumab
vedotin.
Evorpacept
30 mg/kg
IV Q2W• Eligible
Dose patients
Level 2include adults with histologically confirmed, la/mUC who have received prior
Evorpacept
30 mg/kg
IV Q2W
platinum-based chemotherapy
and progressed
duringor after treatment with a PD-1/L1 inhibitor.
• Using a Bayesian Optimal Interval (BOIN) design, patients were administered escalating
Enfortumab
Vedotin
1.25
mg/kg
IV Q2W) combined withdoses of intravenous evorpacept(20 mg/kg
Q2W
or 30
mg/kg
on Days
8, andIV
15onof daysa 28-Day
Cycle
standard enfortumab vedotin(1.251,mg/kg)
1, 8 and
15 of a 28‑day treatment cycle.
Enfortumab Vedotin 1.25 mg/kg IV• Response assessmentson
wereperformed
theainvestigator
per RECIST v1.1.
Days
1, 8, and by
15 of
28-Day Cycle

Backfill Cohort

Evorpacept 30 mg/kg IV Q2W + Enfortumab Vedotin

Backfill Cohort

-40

-100
-80

Median Age, Years (range)
M
F

8060

6040

ECOG PS, n (%)

4020

20 0

Site of Primary-20
0Tumor, n (%)
-40
-20
-60
-40

Subject with Metastatic-80-60
Disease, n (%)

entration (µg/mL)
Concentration (µg/mL)

Acknowledgments: We would like to thank all of the participating patients and their families as well as siteresearch staff; Contact Email: info@alxoncology.com; Presented at ASCO 2024 Annual Meeting.

Partial Response

1000

500
Line of Prior1000

Cancer Therapy, n (%)
500

100
50
100
50

Complete Response

13 Stable(86.7)Disease

2 (13.3)
Complete Response

Evorpacept 20 mg/kg Q2W-80

69 (54-82)
71 (53-86)
Progressive Disease

Not Evaluable

Disease 25 (89.3)
12Progressive(92.3)

1 (7.7)

Not Evaluable

Evorpacept 30 mg/kg Q2W

3 (10.7)

15 (100.0)
11 (84.6)
00
Evorpacept 30 mg/kg Q2W0
1 (7.7)0
1 (7.7)26 (92.9)
0
1 (3.6)
1 (3.6)01

9 (60.0)
6 (40.0)

13 (46.4)
15 (53.6)

BladderUpper Urinary Tract
Urethra
Other
Yes
No

11 (73.3)
2 (13.3)
1 (6.7)1 (6.7)14 (93.3)
1 (6.7)4 (30.8)
9 (69.2)
9 (69.2)
2 (15.4)
2 (15.4)0
12 (92.3)
1 (7.7)4250(33.3)300
1 (7.1)
3 (25.0) (days)
Time from Initiationof Treatment
Peritoneum
3 (25.0) 300
50
100
150 3 (21.4)200250
Lung
6 (42.9) of Treatment
4 (33.3)(days)
Time from Initiation
Lymph node
9 (64.3)
7 (58.3)Other
6 (42.9)0
1st line
2nd Line≥3rd Line100

4 (28.6) 200
150

0
9 (60.0)
6 (40.0)

3 (23.1)
8 (61.5)
2 (15.4)

7 (46.7)

3 (23.1)

10 (35.7)

6 (40.0)

4 (30.8)

10 (35.7)

5 (33.3)

4 (30.8)

9 (32.1)

6 (40.0)

2 (15.4)

8 (28.6)

100

150

200

250

300

5 (33.3)

3 (23.1)

8 (28.6)

Rash Maculo-Papular500

5 (33.3)

3 (23.1)

8 (28.6)

Urinary Tract Infection (UTI)

5 (33.3)

3 (23.1)

8 (28.6)

4 (26.7)

3 (23.1)

7 (25.0)

4 (26.7)

3 (23.1)

7 (25.0)

Blood Creatinine Increased

4 (26.7)

3 (23.1)

7 (25.0)

Rash Pustular

2 (13.3)

5 (38.5)

7 (25.0)20 mg/kg

50

51

Fc domain mutated toeliminateFcγ
receptoreliminateFcγ
receptor
EVO
20
mg/kg
bindingandminimizebinding andN=15
minimize
associatedassociated toxicity
toxicityn (%)

30 mg/kg

Gr 2

Gr 3

Gr 4

Subjects with atLeast One AE

2 (13.3) 7 (46.7) 3 (20.0) 2 (13.3) 4 (30.8) 5 (38.5)

1 (7.7)1 (7.7)25 (89.3)

Fatigue

2 (13.3) 4 (26.7) 3 (20.0)

NauseaALT Increased
AST Increased

400

Gr 2

Gr 3

2 (13.3) 2 (13.3)
3 (20.0)
3 (20.0)

1 (6.7)1 (6.7)

SIRPα
SIRPα

0
0
0

Gr 4

0
0
0
0

Gr 1

2 (15.4) 2 (15.4)
2 (15.4) 4 (30.8)

Evorpacept
Evorpacept

3 (23.1)

3 (23.1)
CD47
CD47

0
0

0
0
0
0

CancerCancer Cell
Cell

0
0
0
0

13 (46.4)

7 (25.0)

Diarrhea

2 (13.3)

1 (6.7)00

Nectin-4
Nectin-40
3 (23.1)

00

6 (21.4)03 (20.0)00
1 (7.7)1 (7.7)
Enfortumab
Enfortumab Vedotin
Vedotin00

5 (17.9)000

5 (17.9)

Decreased Appetite
Lymphocyte Count
Decreased

1 (6.7)

Rash Maculo-Papular

1 (6.7)Fc
Fc Receptor
Receptor

Macrophage
Macrophage

2 (13.3)

2 (13.3)

0

0

0

0

3 (23.1)

1 (7.7)00

1 (7.7)1 (7.7)0

1 (7.7)00

6 (21.4)

5 (17.9)• There were no treatment related deaths on the study.
• 4/28 (14.3%) patients experienced at least one SAE related to EVO.
• EVO 20 mg/kg Q2W reported 2 SAEs (blood creatinine increase, UTI).
Dose
Level
11
Dose
Level
• EVO 30 mg/kg Q2WEvorpacept
reported 3 SAEsmg/kg(rash maculo-papular,
anemia and thrombocytopenia).
Evorpacept 20
20 mg/kg IV
IV Q2W
Q2W

1 (3.6)0

1 (3.6)

0

0

0

0

0

1

0

1 (3.6)

0

0

0

0

0

0

0

1

1 (3.6)000

1 (3.6)336

0Partial Response-20

Complete Response

Progressive Disease

Not Evaluable

Figure 5. Percent Change in Target Lesions Over Time in Response Evaluable Subjects
-40
100
-60
80
-80
60
-100
40

Evorpacept 20 mg/kg Q2W

Evorpacept 30 mg/kg Q2W

Partial Response

20

Stable Disease

Complete Response

Progressive Disease

Not Evaluable

0
100
-20

Evorpacept 20 mg/kg Q2W

Evorpacept 30 mg/kg Q2W

80
-40
60
-60
40
-80

Baseline
0

50

100

150

200

250

300

350

Time from Initiation of Treatment (days)

-20

400

• The majority-40 of patients at both dose levels (20 mg/kg Q2W and 30 mg/kg Q2W) reported adecrease in the size of target lesions with EVO+EV therapy.
1000
-60

500
-80

Evorpacept 30 mg/kg IV Q2W + Enfortumab Vedotin

Total
N=22
n (%)
2 (9.1)

Partial Response (PR)

7 (50.0)

4 (50.0)

11 (50.0)

Stable Disease (SD)

5 (35.7)

3 (37.5)

8 (36.4)

Progressive Disease (PD)0

1 (12.5)

1 (4.5)

Objective Response (CR+PR)

9

4

13

Rate of Objective Response (CR+PR)

64.3

50

59.1

Best % Change in Target Lesion from Baseline
Figure 4a. Evorpacept 20 mg/kg Q2W

Evorpacept
Preliminary
Phase
1a
PK
Resultsfor-100
ASPEN-07
100 Baseline
50
100
150
200
250
300
350
400
Time from Initiation of Treatment (days)

50

Figure 6. Evorpacept Concentration-Time Profiles Following Evorpacept IV Infusion
at 20 mg/kg Q2W & 30 mg/kg Q2W
10
1000
5
500
20 mg/kg

1
100
50

0

24

48

72

96

120

144

168

192

Time (hour)

216

240

264

288

30 mg/kg

312

336

10
5

20 mg/kg

1

100
100

0

24

48

72

96

80
80

120

144

168

192

Time (hour)

216

240

264

288

30 mg/kg

312

336

Table 6. Evorpacept PK Parameters Following IV Infusion at 20 mg/kg Q2W &30 mg/kg Q2W

60
60
40
40
20
20
0
0
-20
-20
-40
-40
-60
-60

Parameters

20 mg/kg Q2W(N=5)

30 mg/kg Q2W(N=5)

Cmax (µg/mL)

474 ± 182

782 ± 298

AUClast (µg*h/mL)

50300 ± 12500

54600 ± 10000

CL (mL/h/kg)

0.323 ± 0.0894

0.389 ± 0.0686

Vss (mL/kg)

70.8 ± 14.7

81.2 ± 15.7

Parameters presented as mean ± SD.

-80
-80
-100
-100

Stable Disease

20
-100

0

• Overall, evorpacept exhibited dose-proportional PK, consistent with results from prior studies2.
Complete Response
Complete Response

Partial Response
Partial Response

Progressive Disease
Progressive Disease

Figure 4b. Evorpacept 30 mg/kg Q2W

Stable Disease
Stable Disease

Conclusion

Not Evaluable
Not Evaluable

100
100

7 (25.0)

2 (13.3)

01

2 (14.3)

10 (35.7)

Blood Alkaline
Phosphatase Increase

1 (6.7)0Notes: Best overall unconfirmed response (BOR) is CR or PR using RECIST v1.1; median follow up of response evaluable population was
5.8 months; Tumor assessments includes all scans reported at baseline, during the treatment period and during follow up unless patient
withdrew consent or started a new anti-cancer therapy; Response evaluable population = all enrolled patients who received at least one
dose of study drug and have at least one post-baseline scan done.

Total
N=28
n (%)

Gr 1

400

EVO 30 mg/kg
N=13
n (%)

0

EVO 30 mg/kg Q2W
EVO 20 mg/kg Q2W
N=14 Cohort
N=8
Backfill
n (%)
n (%)

Decreased Appetite

7 (25.0)

4 (14.3)0400Complete Response (CR)

3 (23.1)

1

Enfortumab Vedotin 1.25 mg/kg IV
Table 5: Best Overall
Response
byofRECIST
v1.1Cycle
on Days
1, 8, and 15
a 28-Day350

4 (26.7)

0 Backfill
0 Cohort
0

1• Among 8 response evaluable patients at EVO 30 mg/kg Q2W:
• ORR=50% (4 PR, 3 SD and 1 PD).
• 1 out of 4 responders was confirmed.

8 (28.6)

100

0

0

0

Evorpacept
30 mg/kg
IV Q2W + Enfortumab Vedotin
Evorpacept
30 mg/kg
IV Q2W

4 (26.7)(30.8)Timefrom Initiation of 4Treatment(days) 8 (28.6)

1000

0

Gr 4

Enfortumab
Vedotin
1.25IV
mg/kg
IV
Evorpacept
30
mg/kg
Q2W
0
0
1
0
0
on Days 1, 8, and 15 of a 28-Day Cycle

3 (23.1)

Inactive
Inactive
Fc
Fc Domain
Domain26 (92.9)
2 (7.1)3 (10.7)
17 (60.7)
8 (28.6)

11 (39.3)

0

Gr 3• Among 14 response evaluable patients at EVO 20 mg/kg Q2W:
• ORR=64.3% (2 CR, 7 PR and 5 SD).
Backfill Cohort•
6 out of
Dose Level
2 9 responders were confirmed.

Table 3: Most Common Fc
EVO
Related Adverse Events Occurring in ≥15% of Patients
domain mutated to

20 (71.4)
4 (14.3)
3 (10.7)
1 (3.6)8 (30.8)350
4 (15.4)
6 350(23.1)
10 (38.5)
16 (61.5)
6 (23.1)

6 (46.2)

1

Gr 2

Total
N=28
n (%)

mg/kg
+ Enfortumab
on Days
1,Evorpacept
8, and15 of20
aORR=59%
28-DayIV
Cycle• Among 22 response
evaluable
patients,(2Q2W
CR, 11
PR, 8 SD andVedotin
1 PD).

Optimized,
picomolar
Optimized,
picomolar
30 mg/kg: thrombocytopenia,
anemia(n=1 each).
bindingaffinitybinding affinity

Total
N=28

White
Black
Evorpacept 20 mg/kg Q2W
Asian
Other

-100
-80
Site of Metastatic Baseline Liver50
Disease, n (%)-100
Bone
Baseline

EVO 30 mg/kg
N=13Partial Response 75 (53-86)
Stable Disease-100

Evorpacept 30 mg/kg IV Q2W + Enfortumab Vedotin

References: 1. Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer 2017. May;76:100109; 2. Lakhani NJ et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients withadvanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and doseexpansion study. Lancet Oncol 2021 Dec;22(12):1740-1751; 3. Rosenberg JE et al. EV-301 long-term outcomes:
24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously
treated advanced urothelial carcinoma. Annals of Oncology 2023 Sept;34:1047-1054; 4. Powles T et al. Enfortumab
vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021 Mar 25;384(12):1125-1135.

EVO 20 mg/kg
N=15-60-8010080-60

5 (33.3)

1

EVO 30 mg/kg
N=13

Initial Activity
of
EVO
+
EV
Backfill
Enfortumab Vedotin 1.25 mg/kg
IVCohort

0 adverse
24
48event
72 was96reported
120 144168 (89.3%)
192 216240 264 288 312• At least
one EVO related
in 25/28
patients.
High
High Affinity
Affinity CD47
CD47
Timewere(hour)• EVO
relatedadverseeventsoccurring
in
≥15%
of
patients
mostly low grade.
Binding
Domainsof
SIRPα
Binding Domains of SIRPα• The most common EVO related adverse events were fatigue, nausea, AST and ALT increased.
• Grade 4 EVO related adverse events at 20 mg/kg: neutrophil count decrease (n=2); and at

Table 1. Patient-60Baseline Characteristics

Race, n (%)-40

Aspartate Aminotransferase (AST)
10
Increased• 26/28 (92.9%) patients
had metastases, with the most common sites being lymph nodes (61.5%),
0

100

-20

Thrombocytopenia
DoseLevel 25 (33.3)

Anemia1001 [EVO 20 mg/kg Q2W], and 13 subjects with dose level 2 [EVO 30 mg/kg Q2W] inwith dose levela 28-day cycle alongwith EV 1.25 mg/kg.
8060• The median age was 71 (range 53 - 86) years, and baseline ECOG scores were 0 (n=13, 46.4%) or
1 (n=15, 53.6%).6040• For most patients,
4020 the primary tumor site was bladder (71.4%).

Sex, n (%)

0

Rash Maculo-Papular

Constipation

Alopecia

Not Evaluable• As of April 3, 2024, 28 EV-naïve patients were treated in the Phase 1a portion, including 15 patients% Change from Baseline% Change Lesions
from Baseline
Measurable
Measurable Lesions

requires both the inhibition of the myeloid CD47/SIRPα checkpoint and activation of themacrophage’s
FcyR
Dose Level
1 by an anti-cancer specific antibody.

12 (42.9)

Increased-20-40• Maximizing antibody dependent cellular phagocytosis (ADCP) in the tumor microenvironment

3 (23.1)

Baseline (ALT)50
Alanine Aminotransferase

Evorpacept 30 mg/kg IV Q2W + Enfortumab Vedotin

Progressive Disease

Enfortumab Vedotin

9 (60.0)20

Abnormal Weight
Loss
-100

0-20

Patient Baseline
Characteristics
100

Nectin-4
Enfortumab Vedotin

14 (50.0)

Pruritus

Progressive Disease
Not Evaluable
Complete Response
Partial Response

Cancer Cell

5 (38.5)

Hyperglycemia-100

Cancer Cell

9 (60.0)4020% Change from Measurable%Baseline
Change Lesion
from Measurable
Baseline Lesion

CD47

Fatigue

40

0Percent Change in the Target Lesions Over Time

Evorpacept
20 mg/kg
IV Q2W + Enfortumab Vedotin
Evorpacept
20
mg/kg
IV
Q2W
0
1
0
0
0
0
0

Blood Creatinine
Increase

UTI

27 (96.4)

6040

Enfortumab Vedotin 1.25 mg/kg IV
on Days 1, 8, and 15 of a 28-Day Cycle

60

N=13
n (%)

Total
N=28
n (%)

12 (92.3)

Diarrhea-40-60

SIRPα

N=15
n (%)

Evorpacept
Q2W
EVO 3030mg/kg
mg/kg

15 (100.0)

NauseaEvorpacept 30 mg/kg IV Q2W

8060-20-40

Evorpacept

Macrophage

Dose Level 2

Dose Level 1

Progressive Disease

Subjects with at Least One AE

Dysgeusia

10080

20 0

Evorpacept

Fc Receptor

Evorpacept 20 mg/kg IV Q2W + Enfortumab Vedotin% Change from Measurable%Baseline
Change Lesion
from Measurable
Baseline Lesion• Fc domain enables

Evorpacept 20 mg/kg
Q2Wmg/kg
EVO 2080

100

Figure 2. Evorpacept Increases Antibody Dependent Cellular Phagocytosis (ADCP)in Combination with Enfortumab Vedotin

SIRPα
Fc Receptor

100

Backfill Cohort

Figure 1. Evorpacept Potently and Selectively Blocks CD47 Binding to SIRPα

Stable Disease

Enfortumab
IV Gr 1
Gr 1 Vedotin
Gr 2 1.25
Gr 3mg/kg
Gr 4
on Days 1, 8, and 15 of a 28-Day Cycle

AnemiaComplete
Response Events
Not Evaluable
Table 2: Most Common Treatment Emergent
AdverseDue to Any Cause
Occurring in ≥25% of Patientsthe FcyR on the macrophage.

High Affinity CD47
Binding Domains of SIRPαHigh Affinity CD47
Binding Domains of SIRPα
Optimized, picomolarbinding affinity
Optimized, picomolarbinding affinity
Fc domain mutated toeliminate Fcγ receptor
Inactive
minimize
Fc Domain
Fcbindingdomainandmutatedtoassociatedeliminate
Fcγtoxicity
receptor
Inactivebinding and minimize
Fc Domain
associated toxicity

Subjects withat Least One SAE

hyperglycemia,-100
and pruritis.

Evorpacept 20 mg/kg IV Q2W• Enfortumab vedotin (EV) is a nectin-4-directed antibody drug conjugate (ADC) which engages
tolerability and initial activity of EVO + EV in patients with locally advanced or metastatic
urothelial carcinoma (la/mUC).

EVO 20 mg/kg
N=15• The most common TEAEs due to any cause were fatigue, dysgeusia, nausea, diarrhea,

Dose Level 1• Here, we present results from the Phase 1a part of the ASPEN-07 study evaluating the safety,-20

were observed, and a maximum tolerated dose (MTD) was not reached.
• At least one all -60
causality treatment emergent adverse event (TEAE) was reported in
27/28 (96.4%) patients.
-80

Figure 3. Phase 1a Study Schema

20
-100

Dose Level 1
Macrophage
Evorpacept
20
mg/kgEvents
IV Q2W(SAEs)
Table 4: EVO Related Serious Adverse

0%%Change
Changefrom
fromMeasurable
Measurable
BaselineLesion
LesionBaseline• Evorpacept (EVO) is a CD47 blocker with an inactivated Fc effector domain that minimizes

Enfortumab Vedotin

80
80%%Change
Changefrom
fromMeasurable
Measurable
Baseline
BaselineLesion
Lesionto ignore the cell on which CD47 is expressed. Tumors upregulate CD47 to evade the innate
immune response.
1

20• EVO in combination
with EV was generally well tolerated. No dose limiting toxicities (DLT)-40% Change from Baseline
Measurable Lesions• CD47, a marker of self, engages signal regulatory protein alpha (SIRPα) and signals macrophages• BOIN design; N=approx. 30 (15 per dose-level).
• Previously treated locally advanced or metastatic urothelial carcinoma.

Evorpacept Concentration (µg/mL)

Background

SafetyPhase 1a: Dose Escalation

40-80

Evorpacept% Change from Baseline
Evorpacept Concentration(µg/mL) Concentration (µg/mL)% Change from Baseline
Measurable Lesions Measurable Lesions% Change from Measurable
Baseline Lesion

1

60
60

Evorpacept was generally well tolerated in combination with enfortumab vedotin anddemonstrates promising preliminary activity in patients with la/mUC.

40
40• This is the first study, to our knowledge, reporting data on the combination of a CD47

blocking agent in combination with an ADC in la/mUC.
• No dose limiting toxicities were observed with EVO + EV, and there were no treatment
related deaths on the study.
• No maximum tolerated dose was reached, and the maximum administered EVO dosewas 30 mg/kg Q2W.
• EVO exhibited dose proportional PK in combination with EV.

20
20
0
0
-20
-20
-40
-40

• EVO+EV displays promising initial clinical activity with an ORR of 59% (Benchmark EV

-60
-60

ORR of 41%)3,4.
• Further investigation in this heavily pretreated population, including patients with prior
EV exposure, is ongoing (NCT05524545).

-80
-80
-100
-100

Partial Response
Partial Response

Stable Disease
Stable Disease

Complete Response
Complete Response

Progressive Disease
Progressive Disease

Not Evaluable
Not Evaluable